Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with... It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity.
- Mechanism
- Curator reviewed
Aleglitazar was rationally designed to be an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. Agonistic action at PPARα controls lipid levels, which improves dyslipidemia, and agonistic action at PPARγ controls glucose levels, which improves insulin sensitivity in diabetes.
- Primary indication
- Investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity.Curator reviewed
- Formula / weight
- C24H23NO5S · 437.508 g/mol (avg)
- Code names
- R-1439 · Ro-0728804
Resolves to
DAYKLWSKQJBGCS-NRFANRHFSA-NSMILESCO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=OWhat you can answer from here — as of February 21, 2021
Which drugs share a target with Aleglitazar, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account